Competitor landscape
A companion to the July 9 acquisition-channels & SEO analysis. That doc found Ambiki nearly invisible on buyer-intent search; this one asks “invisible behind whom?”, profiling the full competitive set across positioning, price, reviews, and the decisive axis: who owns the discovery funnel.
The company Ambiki is set up to beat (Fusion/Ensora, the incumbent it out-features and under-prices) is not the company winning new buyers. On generic buyer-intent search the leaders are content-native challengers (TheraPlatform, ClinicNote, SPRY) and Reddit, while Fusion/Ensora shows up mostly on its own branded-alternative terms, coasting on installed-base brand.
Data gathered July 9, 2026 via Serper.dev SERP data (134 keywords, tagged by discipline), Capterra/G2, and vendor sites.
The finding
The company Ambiki is set up to beat (Fusion/Ensora, the incumbent it out-features and under-prices) is not the company winning new buyers. The Serper share-of-SERP data is unambiguous: on generic buyer-intent searches, the leaders are content-native challengers (TheraPlatform, ClinicNote, SPRY) and Reddit, while Fusion/Ensora shows up mostly on its own branded-alternative terms, coasting on installed-base brand.
That splits the competitive set into two groups that demand different responses:
Ambiki is optimized to win the fight it’s already in, and absent from the fight that decides the market.
The strategic sentence for the CCO pitch: Ambiki is optimized to win the fight it’s already in (the demo vs. Fusion) and absent from the fight that decides the market (the search vs. TheraPlatform, ClinicNote, and Reddit).
Eight vendors across rating, positioning, price, discovery-SEO strength, and the key vulnerability each presents.
| Vendor | Capterra rating / #reviews | Positioning | Price (indicative) | Discovery-SEO strength* | Key vulnerability |
|---|---|---|---|---|---|
| Ambiki | 4.9 / 14 | Pediatric SLP/OT/PT; free-tools + AI; price | $59 + à-la-carte | Absent (branded/self-compare only) | Invisible pre-demand; thin reviews; sub-scale |
| Fusion / Ensora | 4.3 / 707 | Pediatric therapy incumbent (PE rollup) | Premier $189 +$89/user | Low: 16%, own-brand terms | Price creep, dated UI, faceless: Ambiki’s ideal target |
| TheraPlatform | 4.3 / ~65 | Teletherapy-first SLP/OT + practice mgmt | $39–$79/mo | Highest: 52%, avg #3.6 | Small review base; generalist depth vs. pediatric-native |
| ClinicNote | (unlisted) / ~117 speech clinics | Purpose-built SLP/audiology; discovery-call sale | ~$60–70/mo | High: 21%, avg #3.6 | Small; narrow; closest strategic twin to Ambiki |
| SPRY | 4.9 (Capterra) / 4.8 (G2) | AI-native rehab EMR; metric-driven (“98% clean claims”) | ~$100–150/mo/prov + RCM 4–6% | Broad: 36%, avg #6.3 | PT-first (SLP newer); self-serving listicles |
| SimplePractice | 4.6 / ~2,826 | Generalist behavioral-health-origin platform | $49 + add-ons | Medium: 31%, avg #5.2 | Built for mental health, not rehab/pediatric depth |
| WebPT | 4.2 / 493 | Enterprise rehab (PT-led), multi-disciplinary | High / “expensive” | Medium: 21%, avg #4.5 (leads PT) | Price, speed/outage complaints; PT-centric |
| Zanda | – | All-in-one allied health (broad) | Mid | Low: 10% | Generalist; little pediatric-SLP pull |
*Discovery-SEO strength = presence + average position across the 134-keyword Serper set (seo-share-of-serp-2026-07-09.csv); “% of keywords present / avg position.” Ambiki: 20 of 134, but 15 branded/self-comparison; only 5 non-branded (all #4–#10, all speech).
Appears on 70 of 134 keywords (52%) at an average position of 3.6: more than half the entire category, at a top-4 average, and it leads twodisciplines (SLP and OT). It ranks #1 on “best EMR for speech therapy,” “speech therapy EMR software,” and “best speech therapy practice management software” (the one head term Ambiki also cracks, at #4, behind it), and it fully owns its own defensive SERP (“TheraPlatform alternative” returns TheraPlatform at #1, #3, and #4). Positioned teletherapy-first for SLP/OT, priced below Ambiki ($39–79). Its lever is content + category SEO, not a bigger sales team. Crucially, it does this on only ~65 reviews, so its organic dominance is a contentachievement, not a scale one. That’s the proof Ambiki’s gap is execution, not resources.
The closest analog to Ambiki: purpose-built for speech/audiology, ~117 speech clinics, and a discovery-call sales motion(it “starts every sales process with a discovery call… to figure out whether it’s the right fit”), the same human-assisted model Ambiki runs. Yet it ranks on 28 of 134 keywords at an average position of 3.6 (tied for the best of the broad players): #1 on “EMR for SLP private practice.” A business Ambiki’s size, with Ambiki’s motion, beating Ambiki at SEO. It also runs a sharp content play, publishing pieces like “What SLPs Are Actually Paying (And What They’re Not Being Told)” that target price-anxious buyers. This is the single most useful competitor to study, because it’s the controlled experiment: same shape of company, opposite SEO outcome.
Broad footprint (48 of 134 keywords, the second-widest), aggressive self-ranking listicles (“Top Fusion alternatives,” “7 Best Speech Therapy EMRs”), metric-driven positioning (“98% clean claim rate,” “30–40% less documentation time”), 4.9 Capterra / 4.8 G2. PT-first but expanding into SLP. Its listicles are self-serving (it always ranks itself #1), which is both its strength and its exposed flank, a credibility angle for a competitor willing to publish genuinely neutral comparisons. SPRY shows what a well-funded content+AI narrative looks like; it’s the pace-setter Ambiki’s blog is closest in instinct to but far behind in volume and promotion.
Reddit ranks on the front page of many buyer terms: #1 on “AI scribe for speech therapy,” and #1 on “Ambiki vs Fusion” (where Ambiki itself limps in at #4, behind the Reddit thread, Fusion, and ClinicNote). A community forum outranks Ambiki on Ambiki’s owncomparison search. r/slp and SLP Facebook groups are where clinicians actually trade EMR recommendations (the June 1 memo flagged Ambiki’s absence there). This channel can’t be bought, rewards authentic founder/clinician presence, and has direct SEO value because the threads themselves rank.
Tagging the 134 keywords by discipline (seo-by-discipline-2026-07-09.csv) shows there is no single “category leader” to dethrone: each therapy discipline has its own landlord, and Ambiki holds ground in only one.
| Discipline | SERP leader(s) | Ambiki’s visibility | Takeaway |
|---|---|---|---|
| SLP (speech) | TheraPlatform (23), SPRY (19), ClinicNote (18) | 5 non-branded ranks (its only footing) | Contested but where Ambiki belongs |
| OT (occupational) | TheraPlatform (13), SPRY (9), WebPT (8) | 0 | TheraPlatform + WebPT own it; Ambiki absent |
| PT (physical) | WebPT (8), SPRY (6), TheraPlatform (5) | 0 | WebPT’s home turf; Ambiki absent |
| ABA / behavioral | aggregators only (GetApp 2, Capterra 1) | 0 | Whitespace among therapy-EMRs, but ABA-native tools (CentralReach, Rethink) own it off-set |
| Feeding | thin (TheraPlatform 1, ClinicNote 1) | 0 | Too small to read; a peds sub-niche to watch |
The strategic reads: (1) TheraPlatform is the only true multi-discipline SEO threat (leads SLP and OT, top-3 in PT). (2) WebPT is a PT-specific wall; any Ambiki PT push runs straight into it. (3) Ambiki’s SLP-only footing argues for a speech-first distribution focus before spreading into OT/PT/ABA, each of which is a from-zero fight against an entrenched, discipline-specific leader. This is the distribution-side echo of the ICP argument in the June 1 memo and the “focus the core ICP to protect NRR” logic in the June 5 model. Full discipline breakdown in the acquisition doc §3.4.
707 reviews at 4.3, 200k+ providers, but organically coasting (mid-pack SERP presence, mostly on its own branded terms). The secret shopshowed Ambiki out-features and roughly halves its price. The reviews and the market narrative hand Ambiki its attack lines: PE-driven price increases, “outdated interface,” faceless rollup. Fusion is the ideal named target for comparison content (“Ambiki vs Fusion,” “Fusion alternative”), precisely the terms where Ambiki is currently absent and a Reddit thread wins.
4.2 / 493, positioned enterprise/PT-led. Reviews cite high price, fee-nickel-and-diming (charging for reminders), and speed/outage issues. Not a direct pediatric-SLP competitor, but it appears in the consideration set for multi-disciplinary practices. Its weaknesses (price, performance) rhyme with Fusion’s, a shared “legacy, expensive, clunky” frame Ambiki can own the opposite of.
4.6 / ~2,826: huge, but behavioral-health-origin; the secret-shop Fusion rep herself attacked it as “built for mental health, not rehab.” It’s the incumbent in the otherhalf of Ambiki’s secret-shop persona (the practice migrating off SimplePractice). Its pediatric/rehab depth is shallow, its add-on pricing creeps; Ambiki’s pediatric-native depth is the clean contrast. A meaningful migration-sourceto build “switching from SimplePractice” content and tooling around.
The shape matches the secret-shop report exactly: excellent assets, no commercial distribution.Ambiki is a better product than its market position reflects, gated by a demand engine pointed at clinicians and a discovery presence that’s effectively zero.
Each maps to the acquisition-channel moves (companion doc §9) and a June 5 KPI.
Battlecards and win/loss shouldn’t center only on Fusion; they must cover TheraPlatform and ClinicNote, who take deals before Ambiki is ever contacted. KPI: win rate by competitor, expanded to include the challengers, not just the incumbent.
They prove a company Ambiki’s size can rank #1–3 on buyer terms. Comparison pages, “vs” pages, price-transparency content, category guides: the exact SERPs where Ambiki is absent. KPI: marketing-sourced pipeline %, non-paid trial mix.
“Ambiki vs Fusion / WebPT / SimplePractice” content built around price creep, dated UI, and pediatric-native depth: Ambiki’s genuine edges. KPI: win rate vs. Fusion/SimplePractice.
It ranks, it’s unowned, and it fits a founder-led, built-by-therapists brand. KPI: non-paid trial-source mix.
No competitor is bidding the high-intent terms (Serper found zero ads); a small campaign buys presence in the consideration set while organic compounds. KPI: CAC by path, magic number.
The rating beats everyone; the volume beats no one. Systematic review generation turns a latent strength into a visible one that also lifts aggregator SERP placement. KPI:trial-source mix; win rate (blunts the “risky startup” line).
Bottom line
Ambiki’s competitive problem is not that a stronger product is beating it. It’s that weaker-or-equal products with stronger distribution are reaching the buyer first. That is the most fixable kind of competitive disadvantage, and fixing distribution is the CCO’s core mandate.
seo-rankings-2026-07-09.csv, seo-share-of-serp-2026-07-09.csv, seo-by-discipline-2026-07-09.csv (generated by serper_seo_rank_tracker.py).clients/Ambiki/).